Pfizer boosts China presence with US$350m biotech plant
Facility to be completed in 2018, will make biologics and cheaper versions
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
Beijing
PFIZER Inc will invest US$350 million in eastern China on a plant for biotechnology drugs, bolstering its presence in the world's second largest pharmaceutical market despite slowing economic growth in the country and rising pressure on prices for medicines.
The new facility in eastern Hangzhou city is expected to be completed in 2018 and will manufacture biologics, or complex medicines made from living organisms, as well as cheaper copycat versions known as biosimilars for patients in China and across the world, Pfizer said in an e-mailed statement Tuesday.
Share with us your feedback on BT's products and services
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
